About this item:

219 Views | 106 Downloads

Author Notes:

Corresponding author: Baowei Fei: bfei@emory.edu and http://www.feilab.org

The authors have participated in sponsored research involving 18F-fluciclovine among other radiotracers.

Emory University is eligible to receive royalties for 18F-fluciclovine.

The study was approved by the IRB of Emory University.


Research Funding:

This work was partially supported by NIH Grants CA156775 and CA176684.


  • Image registration
  • Image segmentation
  • Magnetic resonance imaging (MRI)
  • Molecular imaging
  • Positron emission tomography (PET)
  • Prostate cancer
  • Targeted biopsy

Molecular imaging and fusion targeted biopsy of the prostate


Journal Title:

Clinical and Translational Imaging


Volume 5, Number 1


, Pages 29-43

Type of Work:

Article | Post-print: After Peer Review


Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

Copyright information:

© 2016, Italian Association of Nuclear Medicine and Molecular Imaging.

Export to EndNote